← ANALYST RATINGS · TIPRANKS
Tyra Bioscience (TYRA): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $47.40, the highest $59.00, the lowest $29.00. The average is +155.9% from the last price of $18.52.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.50 → $19.00−2.6% | Hold | +2.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $19.00 → $18.50−2.6% | Hold | −0.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $19.50 → $19.00−2.6% | Hold | +2.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $19.00 → $18.50−2.6% | Hold | −0.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $20.00 → $19.50−2.5% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $19.00 → $18.50−2.6% | Hold | −0.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $59.00 | Buy | +218.6% | Reiterated | 30.09.26on TipRanks 05:25 | −0.3%next day −4.1% · 5 days −8.7% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $50.00 | Buy | +170.0% | Reiterated | 23.09.26on TipRanks Sep 24 03:25 | −8.4%next day −3.4% · 5 days −5.2% | ↗ |
| Mazahir Alimohamed★★★★★★★★★★#9079 · hits 50% · avg −1.5% | Oppenheimer | $50.00 → $40.00−20.0% | Buy | +116.0% | Reiterated | 22.09.26on TipRanks 08:00 | −0.3%next day −8.4% · 5 days −12.9% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $50.00 | Buy | +170.0% | Reiterated | 22.09.26on TipRanks 07:10 | −0.3%next day −8.4% · 5 days −12.9% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $30.00 → $29.00−3.3% | Buy | +56.6% | Reiterated | 22.09.26on TipRanks 06:20 | −0.3%next day −8.4% · 5 days −12.9% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $53.00 | Buy | +186.2% | Reiterated | 11.09.26on TipRanks Oct 1 10:25 | −7.3%next day +14.2% · 5 days +16.9% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $56.00 | Buy | +202.4% | Reiterated | 10.09.26on TipRanks 07:50 | +7.6%next day −7.3% · 5 days +3.2% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 09.09.26on TipRanks 10:55 | −17.2%next day +7.6% · 5 days +11.7% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $56.00 | Buy | +202.4% | Reiterated | 08.09.26on TipRanks 07:25 | −6.2%next day −17.2% · 5 days −3.7% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $39.00 | Buy | +110.6% | Reiterated | 08.09.26on TipRanks 06:25 | −6.2%next day −17.2% · 5 days −3.7% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $44.00 → $42.00−4.5% | Buy | +126.8% | Reiterated | 05.08.26on TipRanks 15:20 | −20.8%next day +5.0% · 5 days −1.9% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Hold | — | Initiated | 19.05.26on TipRanks 06:15 | −4.6%next day −2.1% · 5 days −4.1% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 13.05.26on TipRanks 11:35 | +3.2%next day +0.1% · 5 days −7.6% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $54.00 | Buy | +191.6% | Initiated | 15.04.26on TipRanks Apr 14 16:20 | −1.6%next day +0.2% · 5 days +5.2% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | — | Buy | — | Reiterated | 04.03.26on TipRanks Mar 5 01:25 | +6.1%next day −1.5% · 5 days +4.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Tyra Bioscience
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $47.40 at a price of $21.87 (+116.7%); now: $47.40 at $18.52 (+155.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 12 | 15 | 21 | 24 | 19 |
| Buy | 20 | 16 | 13 | 3 | 6 | 5 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.67 (from $-0.76 to $-0.47). Last quarter: $-0.69.
Best top-analyst consensus in the sector · Healthcare
About Tyra Bioscience
- CEO: Todd Harris
- Employees: 87
- 2656 State Street, Carlsbad, CA, 92008, US
- www.tyra.bio
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗